SEC Form 4 · accession 0000886163-18-000017
LIGAND PHARMACEUTICALS INC · LGND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John L Higgins
Officer — Chief Executive Officer · Director
Period of report
Feb 15, 2018
Accepted (ET)
Feb 16, 2018 · 5:38 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000886163
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Feb 15, 2018 | S | 9,000 | $157.031 | D | 102,700 | D | |
| Common StockF3 | Feb 15, 2018 | F | 2,635 | $157.18 | D | 100,065 | D | |
| Common StockF4 | Feb 15, 2018 | F | 1,918 | $157.18 | D | 98,147 | D | |
| Common StockF5 | Feb 15, 2018 | F | 1,689 | $157.18 | D | 96,458 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 20, 2017, in accordance with Rule 10b5-1.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $156.09 to $158.88, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/10/2015.
- F4Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/11/2016.
- F5Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/24/2017.